LONDON (ShareCast) - (ShareCast News) - Life sciences business OptiBiotix Health announced plans for a US launch of it cholesterol and blood pressure lowering product 'LPLDL' at 'Supply Side West in Las Vegas' on Thursday, to take place on 27 and 28 September.
The AIM-traded firm said the launch followed the global manufacturing and supply agreement with Sacco announced on 22 August.

It said the Supply Side West trade show brought together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries, and was viewed as "one of the world's leading" trade fairs for the food and drinks industry.

"OptiBiotix has made significant progress in raising industry awareness of its LPLDL strain," said CEO Stephen O'Hara.

"This has created a high level of interest in commercialising products containing LPLDL as a component in higher value branded products in markets globally."

OptiBiotix said it will co-exhibit with Sacco, and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain at the show.

They would include 'CholBiome' - a proprietary formulation containing LPLDL to reduce cholesterol levels and blood pressure; and 'CardioBiome' - a proprietary formulation containing LPLDL to reduce a "wide range" of cardiovascular disease factors and improve long term heart health.

OptiBiotix said the US launch of LPLDL, CholBiome and CardioBiome at Supply Side West was the first of a number of commercial steps taken to supply LPLDL to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations, and presentations for distribution and sale into the US market.

It described the US as "one of the largest and fastest-growing" probiotic markets in the world, with supplements alone accounting for $2.06bn in sales, with a projected 55% growth to $3.3bn by 2021.

Discussions were reportedly continuing to progress with corporate partners for the manufacture and distribution of products containing LPLDL in the European, Asian and other international markets.

"Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners," Stephen O'Hara added.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE